Cargando…

Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella

Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable tech...

Descripción completa

Detalles Bibliográficos
Autores principales: Micoli, Francesca, Rondini, Simona, Alfini, Renzo, Lanzilao, Luisa, Necchi, Francesca, Negrea, Aurel, Rossi, Omar, Brandt, Cornelia, Clare, Simon, Mastroeni, Pietro, Rappuoli, Rino, Saul, Allan, MacLennan, Calman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187145/
https://www.ncbi.nlm.nih.gov/pubmed/30262653
http://dx.doi.org/10.1073/pnas.1807655115
_version_ 1783362972106620928
author Micoli, Francesca
Rondini, Simona
Alfini, Renzo
Lanzilao, Luisa
Necchi, Francesca
Negrea, Aurel
Rossi, Omar
Brandt, Cornelia
Clare, Simon
Mastroeni, Pietro
Rappuoli, Rino
Saul, Allan
MacLennan, Calman A.
author_facet Micoli, Francesca
Rondini, Simona
Alfini, Renzo
Lanzilao, Luisa
Necchi, Francesca
Negrea, Aurel
Rossi, Omar
Brandt, Cornelia
Clare, Simon
Mastroeni, Pietro
Rappuoli, Rino
Saul, Allan
MacLennan, Calman A.
author_sort Micoli, Francesca
collection PubMed
description Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM(197) glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM(197). Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti–O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella. S. Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance.
format Online
Article
Text
id pubmed-6187145
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-61871452018-10-15 Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella Micoli, Francesca Rondini, Simona Alfini, Renzo Lanzilao, Luisa Necchi, Francesca Negrea, Aurel Rossi, Omar Brandt, Cornelia Clare, Simon Mastroeni, Pietro Rappuoli, Rino Saul, Allan MacLennan, Calman A. Proc Natl Acad Sci U S A Biological Sciences Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM(197) glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM(197). Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti–O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella. S. Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance. National Academy of Sciences 2018-10-09 2018-09-27 /pmc/articles/PMC6187145/ /pubmed/30262653 http://dx.doi.org/10.1073/pnas.1807655115 Text en Copyright © 2018 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Biological Sciences
Micoli, Francesca
Rondini, Simona
Alfini, Renzo
Lanzilao, Luisa
Necchi, Francesca
Negrea, Aurel
Rossi, Omar
Brandt, Cornelia
Clare, Simon
Mastroeni, Pietro
Rappuoli, Rino
Saul, Allan
MacLennan, Calman A.
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title_full Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title_fullStr Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title_full_unstemmed Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title_short Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
title_sort comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal salmonella
topic Biological Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187145/
https://www.ncbi.nlm.nih.gov/pubmed/30262653
http://dx.doi.org/10.1073/pnas.1807655115
work_keys_str_mv AT micolifrancesca comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT rondinisimona comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT alfinirenzo comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT lanzilaoluisa comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT necchifrancesca comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT negreaaurel comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT rossiomar comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT brandtcornelia comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT claresimon comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT mastroenipietro comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT rappuolirino comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT saulallan comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella
AT maclennancalmana comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella